Pulse Biosciences Inc
NASDAQ:PLSE

  • LAST PRICE
    15.1900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    13.7600/ 1
  • Ask / Lots
    16.7500/ 10
  • Open / Previous Close
    --- / 15.1900
  • Day Range
    ---
  • 52 Week Range
    4.5710
    22.6900
  • Volume
    2

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 31, 2024

  • Oct 30, 2024

      Show headlines and story abstract

    • 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: PLSE

      Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
      MIAMI--(BUSINESS WIRE)--October 30, 2024--
      Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation(TM) (nsPFA or nano-PFA) technology, today announced business updates and financial results for the third quarter ended September 30, 2024.

    • 4:05PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: PLSE
      Ended Ended September 30, September 30, ---------------------- --------------------- 2024 2023 2024 2023 ------- ------- ------- ------- Reconciliation of GAAP to non-GAAP Research and development: GAAP Research and development $ 7,703 $ 7,472 $ 21,674 $ 19,998 Less: Stock-based compensation expense (1,108) (982) (3,058) (1,758) Less: Depreciation and amortization (47) (55) (152) (172) Less: Restructuring -- -- -- (38) ------- ------- ------- ------- Non-GAAP Research and development $ 6,548 $ 6,435 $ 18,464 $ 18,030 ======= ======= ======= ======= Reconciliation of GAAP to non-GAAP General and administrative: GAAP General and administrative $ 5,952 $ 3,780 $ 14,322 $ 11,043 Less: Stock-based compensation expense (1,874) (816) (3,735) (2,079) Less: Depreciation and amortization (246) (242) (740) (730) Less: Restructuring -- -- -- (5) ------- ------- ------- ------- Non-GAAP General and administrative $ 3,832 $ 2,722 $ 9,847 $ 8,229 ======= ======= ======= ======= Reconciliation of GAAP to non-GAAP Cost and expenses: GAAP Cost and expenses $ 13,655 $ 11,252 $ 35,996 $ 31,041 Less: Stock-based compensation expense (2,982) (1,798) (6,793) (3,837) Less: Depreciation and amortization (293) (297) (892) (902) Less: Restructuring -- -- -- (43) ------- ------- ------- ------- Non-GAAP Cost and expenses $ 10,380 $ 9,157 $ 28,311 $ 26,259 ======= ======= ======= ======= Reconciliation of GAAP to non-GAAP Net loss: GAAP Net loss $(12,680) $(10,566) $(34,200) $(30,277) Add: Stock-based compensation expense 2,982 1,798 6,793 3,837 Add: Depreciation and amortization 293 297 892 902 Add: Restructuring -- -- -- 43 ------- ------- ------- ------- Non-GAAP Net loss $ (9,405) $ (8,471) $(26,515) $(25,495) ======= ======= ======= =======

Peers Headlines